ECHOIQ LIMITED (ASX: EIQ)
🔗 📄 📈 Back to top
Artificial Intelligence company Echo IQ has launched EchoSolvTM, a new module for Mitral Regurgitation. Mitral Regurgitation is the most common type of heart valve abnormality, often under-diagnosed. EchoSolvTM is an AI-powered decision support solution that enhances identification of chronic Mitral Regurgitation progression.
Echo IQ secures maiden sale of EchoSolvTM AI-backed SaaS technology in Gold Coast Private Hospital, its first sale in an Australian hospital. The deployment of EchoSolvTM follows a successful clinical study where it achieved higher detection rates of severe aortic stenosis than human-only diagnosis. Echo IQ's sales pipeline is building strongly in the US and Australia, with their AI technology expected to help drive better clinical decision-making across various healthcare settings.
Integration Partner agreement between Echo IQ and Core Sound Imaging. EchoSolvTM to be integrated into Studycast platform, making it available to 700 cardiovascular facilities. Acceleration of adoption expected with presence at the ASE Conference in June 2023.
Echo IQ appoints Cassling Diagnostic Imaging as exclusive sales agent for EchoSolvTM in the Mid-West Region, USA Commercial deployment of EchoSolvTM scheduled to commence in an Australian private cardiology practice EchoSolvTM gains traction in the healthcare market, addressing under-diagnosis of structural heart disease with AI decision-support software
Echo IQ partners with MedAxiom, an American College of Cardiology company, to expand commercial footprint in the US. Hydrix Medical appointed as sales partner for Australia, New Zealand, and Singapore, with additional recruitments to strengthen commercial teams. EchoSol vTM, Echo IQ's AI decision-support software, is ready to roll out for structural heart disease.